ALMR vs BIO
ALMR: Alamar Biosciences is a proteomics company providing a high-sensitivity platform for precise protein biomarker detection and analysis to drive medical research and future diagnostics. BIO: Bio-Rad provides essential tools and services for life science research and clinical diagnostics to help advance scientific discovery and improve patient outcomes.
Side-by-side fundamentals
| Metric | ALMR | BIO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $25.91 | $360.40 | |
| Market cap | $1.8B | $10.0B | |
| P/E as of 2026-10-08 | n/a | 43.69 | |
| Net margin FY2025, SEC XBRL | n/a | +29.4% | |
| Gross margin FY2025, SEC XBRL | n/a | +51.9% | |
| Operating margin FY2025, SEC XBRL | n/a | +1.8% | |
| ROE FY2025, SEC XBRL | n/a | +10.2% | |
| ROA FY2025, SEC XBRL | n/a | +7.2% | |
| Debt / equity as of 2026-09-03 | 1.32 | 0.17 | BIO lower |
| Revenue growth (YoY) as of 2026-09-03 | n/a | +1.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -2.7% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | -0.20 | 0.92 | |
| 1-year return as of 2026-10-08 close | n/a | +19.0% |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.